Research on the process and molecular mechanism of inhibiting serous ovarian cancer by PRTN3 and its inhibitor Sivelestat
Whole exome sequencing and bioinformatics analysis identified PRTN3 as a potential molecular marker of serous ovarian cancer, and PRTN3 could significantly affect the prognosis of SOC patients. As an inhibitor of PRTN3, sivelestat can inhibit the expression of PRTN3 in SOC cell lines and reduce their migration ability in vitro. In vivo experiments showed that sivelestat can inhibit the growth of subcutaneous transplanted tumor in nude mice with certain safety.
Authors
- Xiangyun Hu (ORCID: https://orcid.org/0000-0003-3623-8304)
- Ying Ding (ORCID: https://orcid.org/0000-0001-5581-3058)
- Lu-Zhu Chen (ORCID: https://orcid.org/0000-0001-8206-8153)
- Xiaoheng Lv (ORCID: https://orcid.org/0000-0002-3829-1590)
- Yaoyao He (ORCID: https://orcid.org/0000-0002-2631-3617)
- Huainian Zhang
- Yongli Zhang (ORCID: https://orcid.org/0000-0001-7079-7973)
- Sheng Wang (ORCID: https://orcid.org/0009-0002-9891-2405)
- Tao Zhang (ORCID: https://orcid.org/0000-0003-0427-9953)
- Changtao Zheng
- Wei Peng (ORCID: https://orcid.org/0000-0002-8031-8208)
- X.-N. Zhang
Institutions
- Guangdong Pharmaceutical University (CN)
- Wuhan University (CN)
- Longgang Central Hospital (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- Zhongnan Hospital of Wuhan University (CN)
- Hegang People's Hospital (CN)
- Shenzhen Bao'an District People's Hospital (CN)
Publication Details
- Journal
- Journal of Ovarian Research
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1186/s13048-025-01808-x
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China